AT248594T - Irbesartanhaltiges arzneimittel - Google Patents

Irbesartanhaltiges arzneimittel

Info

Publication number
AT248594T
AT248594T AT96304291T AT96304291T AT248594T AT 248594 T AT248594 T AT 248594T AT 96304291 T AT96304291 T AT 96304291T AT 96304291 T AT96304291 T AT 96304291T AT 248594 T AT248594 T AT 248594T
Authority
AT
Austria
Prior art keywords
irbescented
medicinal
Prior art date
Application number
AT96304291T
Other languages
English (en)
Inventor
Cathy C Ku
Omar L Sprockel
Beth A Rubitski
Divyakant S Desai
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US47261895A priority Critical
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of AT248594T publication Critical patent/AT248594T/de
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23876256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT248594(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
AT96304291T 1995-06-07 1996-06-07 Irbesartanhaltiges arzneimittel AT248594T (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US47261895A true 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
AT248594T true AT248594T (de) 2003-09-15

Family

ID=23876256

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02016237T AT503478T (de) 1995-06-07 1996-06-07 Arzneizubereitung enthaltend irbesartan und ein diuretikum
AT96304291T AT248594T (de) 1995-06-07 1996-06-07 Irbesartanhaltiges arzneimittel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02016237T AT503478T (de) 1995-06-07 1996-06-07 Arzneizubereitung enthaltend irbesartan und ein diuretikum

Country Status (24)

Country Link
EP (2) EP1275391B1 (de)
JP (1) JP3162626B2 (de)
KR (1) KR100442719B1 (de)
CN (1) CN1149083C (de)
AR (2) AR002350A1 (de)
AT (2) AT503478T (de)
AU (1) AU702651B2 (de)
CA (1) CA2177772C (de)
CZ (1) CZ291532B6 (de)
DE (2) DE69629755T3 (de)
DK (2) DK1275391T3 (de)
ES (2) ES2363127T3 (de)
HK (1) HK1002384A1 (de)
HU (1) HU229369B1 (de)
IL (1) IL118309A (de)
MX (1) MX9602103A (de)
NO (2) NO310495B1 (de)
NZ (2) NZ329547A (de)
PL (1) PL184893B1 (de)
PT (2) PT747050E (de)
RU (2) RU2181590C2 (de)
SG (1) SG49956A1 (de)
TW (1) TW442301B (de)
ZA (1) ZA9604337B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4575594B2 (ja) * 1998-07-20 2010-11-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 経口用固体剤形のエプロサルタン配合の生体内強化性処方
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
EP1648515B1 (de) * 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidon-kombinationen
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇i̇ Ve Ti̇caret A.Ş. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
JP2005126338A (ja) * 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
CA2568640C (en) * 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006013545A1 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Pharmaceutical compositions of irbesartan
AU2006290309B2 (en) 2005-09-12 2012-04-05 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
RU2469709C2 (ru) * 2005-11-17 2012-12-20 Новартис Аг Фармацевтическая композиция
ES2340701T3 (es) * 2006-01-09 2010-06-08 Krka, D.D., Novo Mesto Composicion farmaceutica solida que comprende irbesartan.
DE102006006588A1 (de) 2006-02-13 2007-08-16 Ratiopharm Gmbh Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung
TWI351399B (en) * 2006-06-12 2011-11-01 Schering Corp Pharmaceutical formulations and compositions of a
DE602007012692D1 (de) 2006-06-16 2011-04-07 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1923053A1 (de) * 2006-09-27 2008-05-21 Novartis AG Pharmazeutische Zusammensetzung umfassend Nilotinib oder dessen Salz
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd DERIVATIVES OF 4-PYRIMIDINASULFAMIDA.
RU2465900C2 (ru) * 2007-04-17 2012-11-10 Рациофарм Гмбх Фармацевтические композиции, содержащие ирбесартан
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Valsartan formülasyonları
ES2349317T3 (es) 2007-11-28 2010-12-29 Laboratorios Lesvi, S.L. Formulaciones farmacéuticas que contienen irbesartán.
CN101327213B (zh) * 2008-06-20 2010-10-13 海南锦瑞制药股份有限公司 厄贝沙坦氢氯噻嗪药用组合物及其制备方法
JP5296456B2 (ja) * 2008-08-26 2013-09-25 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
CA2766884C (en) * 2009-06-30 2016-08-23 Sanofi Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
WO2011010316A1 (en) * 2009-07-20 2011-01-27 Hetero Research Foundation Pharmaceutical compositions of irbesartan
LT2498756T (lt) * 2009-11-09 2019-12-10 Wyeth Llc Neratinibo maleato tablečių sudėtis
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
JP4974255B2 (ja) * 2010-03-16 2012-07-11 塩野義製薬株式会社 アンジオテンシンii受容体拮抗剤の配合剤
JP5459670B2 (ja) * 2010-05-07 2014-04-02 塩野義製薬株式会社 着色顆粒の色素定着化剤
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
KR20130041144A (ko) * 2010-07-08 2013-04-24 라티오팜 게엠베하 데페라시록스의 경구투여용 제제
WO2013100112A1 (ja) * 2011-12-28 2013-07-04 ニプロ株式会社 アンギオテンシンii拮抗作用を有する化合物を含有する固形医薬組成物
CA2873961C (en) 2012-05-14 2017-09-26 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
PL2919903T3 (pl) 2012-11-14 2020-12-14 W.R. Grace & Co. - Conn. Kompozycje zawierające materiał biologicznie aktywny i nieuporządkowany tlenek nieorganiczny
JP5714652B2 (ja) * 2013-06-13 2015-05-07 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6238921B2 (ja) * 2014-02-17 2017-11-29 大原薬品工業株式会社 イルベサルタンを含有する錠剤
JP5978335B2 (ja) * 2015-03-11 2016-08-24 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6199922B2 (ja) * 2015-03-20 2017-09-20 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
JP6445923B2 (ja) * 2015-04-22 2018-12-26 ダイト株式会社 イルベサルタン含有錠剤の調製方法
JP6151413B2 (ja) * 2016-07-25 2017-06-21 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2017141299A (ja) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6233911B2 (ja) * 2017-08-22 2017-11-22 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
JP2018009032A (ja) * 2017-10-19 2018-01-18 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
CN108434112A (zh) * 2018-06-08 2018-08-24 华益药业科技(安徽)有限公司 一种厄贝沙坦片及其制备方法
PH12018000390A1 (en) * 2018-11-20 2020-09-28 Novex Science Pte Ltd Carbocysteine and zinc tablet
JP2019203031A (ja) * 2019-09-06 2019-11-28 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744317C1 (de) 1987-12-28 1989-05-24 Rudolf Dr Rer Nat Kuerner Verwendung von Calciumsulfat zur Verbesserung der Fermentierung organischer Abfallstoffe
EP0400835A1 (de) 1989-05-15 1990-12-05 Merck & Co. Inc. Substituierte Benzimidazole als Angiotensin II-Hemmer
US5164407A (en) 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
IE910913A1 (en) * 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IL99372D0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
EP0502575A1 (de) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituierte 1-(2H)-Isoquinolinone
WO1994009778A1 (en) 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Also Published As

Publication number Publication date
HU9601564D0 (en) 1996-08-28
DK747050T3 (de)
NZ329547A (en) 1998-06-26
DE69629755D1 (de) 2003-10-09
NZ286612A (en) 1998-03-25
DK1275391T3 (da) 2011-07-11
PL314670A1 (en) 1996-12-09
NO962387D0 (no) 1996-06-06
DE69629755T3 (de) 2013-08-08
AR054782A2 (es) 2007-07-18
AU5476396A (en) 1996-12-19
IL118309A (en) 2003-06-24
ZA9604337B (en) 1997-11-28
JP3162626B2 (ja) 2001-05-08
EP0747050A1 (de) 1996-12-11
NO962387L (no) 1996-12-09
NO310393B1 (no) 2001-07-02
CZ163496A3 (en) 1996-12-11
AT503478T (de) 2011-04-15
EP0747050B1 (de) 2003-09-03
ES2205000T3 (es) 2004-05-01
CN1149083C (zh) 2004-05-12
CA2177772C (en) 2007-04-10
NO310495B1 (no) 2001-07-16
JPH08333253A (ja) 1996-12-17
SG49956A1 (en) 1998-06-15
HU9601564A2 (hu) 1998-09-28
DK0747050T4 (da) 2013-05-21
EP1275391A1 (de) 2003-01-15
ES2363127T3 (es) 2011-07-21
PT747050E (pt) 2003-12-31
RU2210368C1 (ru) 2003-08-20
NO20004743L (no) 1996-12-09
EP1275391B1 (de) 2011-03-30
CA2177772A1 (en) 1996-12-08
PT1275391E (pt) 2011-06-30
DE69638348D1 (de) 2011-05-12
EP0747050B2 (de) 2013-02-13
HU9601564A3 (en) 2000-12-28
HU229369B1 (en) 2013-11-28
TW442301B (en) 2001-06-23
DK0747050T3 (da) 2003-12-15
CZ291532B6 (cs) 2003-03-12
CN1144656A (zh) 1997-03-12
IL118309D0 (en) 1996-09-12
AR002350A1 (es) 1998-03-11
MX9602103A (es) 1997-09-30
NO20004743D0 (no) 2000-09-22
ES2205000T5 (es) 2013-05-30
RU2181590C2 (ru) 2002-04-27
DE69629755T2 (de) 2004-07-01
KR970000232A (ko) 1997-01-21
AU702651B2 (en) 1999-02-25
HK1002384A1 (en) 1998-08-21
RU2001130903A (ru) 2004-02-27
PL184893B1 (pl) 2003-01-31
KR100442719B1 (ko) 2004-10-08

Similar Documents

Publication Publication Date Title
DK1419802T3 (da) Gelindkapslingsstruktur
DK0850426T3 (da) Transpondearrangement
DK0747706T3 (da) Adduktbeskyttelsesassay
DK0811095T3 (da) Støttemursystem
DK0747181T3 (da) Afgreningsordning
DK0721330T3 (da) Farmaceutisk præparat
DK0874606T3 (da) Hofteledskålslegemeprotese
DK0757905T3 (da) Nasaldilatatorindretning
DK0824483T3 (da) Dispenser
DK0802921T3 (da) Humant PAK65
DK0790941T3 (da) Tabletdispenser
AT211131T (de) Arylsulfonylaminohydroxamsäurederivate
AT240703T (de) Zwischenwirbelfusionierungseinrichtung
AT281132T (de) Spondylodeseimplantate
AT274838T (de) Nähfadenzange
AT346905T (de) Bleichkatalysatorteilchen
AT210152T (de) Somatostatinpeptide
AT240753T (de) Flüssigkeitsabgabeset
AT234092T (de) 2-alkylpyrrolidine
BR9609888A (pt) Halogenobenzimidazóis
AT418392T (de) Sprühpistolekörper
AU3173095A (en) Novel pharmaceutical product
AT170083T (de) Arzneimittel enthaltend protein-gebundende liposome
EG23826A (en) Pharmaceutical formulations
RU97104916A (ru) Блистерная упаковка

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0747050

Country of ref document: EP